JP2023516280A5 - - Google Patents
Info
- Publication number
- JP2023516280A5 JP2023516280A5 JP2022548140A JP2022548140A JP2023516280A5 JP 2023516280 A5 JP2023516280 A5 JP 2023516280A5 JP 2022548140 A JP2022548140 A JP 2022548140A JP 2022548140 A JP2022548140 A JP 2022548140A JP 2023516280 A5 JP2023516280 A5 JP 2023516280A5
- Authority
- JP
- Japan
- Prior art keywords
- binder
- seq
- nucleic acid
- acid molecule
- recombinant vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971013P | 2020-02-06 | 2020-02-06 | |
| US62/971,013 | 2020-02-06 | ||
| US202062988610P | 2020-03-12 | 2020-03-12 | |
| US62/988,610 | 2020-03-12 | ||
| US202062991408P | 2020-03-18 | 2020-03-18 | |
| US62/991,408 | 2020-03-18 | ||
| US202063041240P | 2020-06-19 | 2020-06-19 | |
| US63/041,240 | 2020-06-19 | ||
| EPPCT/EP2020/077004 | 2020-09-25 | ||
| EPPCT/EP2020/077004 | 2020-09-25 | ||
| GBGB2020508.4A GB202020508D0 (en) | 2020-12-23 | 2020-12-23 | Multivalent sars-cov-2 virus binders |
| GB2020508.4 | 2020-12-23 | ||
| EP21151356 | 2021-01-13 | ||
| EP21151356.9 | 2021-01-13 | ||
| PCT/EP2021/052885 WO2021156490A2 (en) | 2020-02-06 | 2021-02-05 | Corona virus binders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516280A JP2023516280A (ja) | 2023-04-19 |
| JP2023516280A5 true JP2023516280A5 (https=) | 2024-02-02 |
Family
ID=83365410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548140A Pending JP2023516280A (ja) | 2020-02-06 | 2021-02-05 | コロナウイルスバインダー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230227537A1 (https=) |
| EP (1) | EP4100055A2 (https=) |
| JP (1) | JP2023516280A (https=) |
| KR (1) | KR20220166787A (https=) |
| CN (1) | CN116234569A (https=) |
| AU (1) | AU2021217563A1 (https=) |
| CA (1) | CA3166967A1 (https=) |
| IL (1) | IL295389A (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| WO2021228854A1 (en) * | 2020-05-11 | 2021-11-18 | Lysando Ag | Virus neutralization by soluble receptor fragments of the ace-2 receptor |
| AR123469A1 (es) * | 2020-09-10 | 2022-12-07 | Bighat Biosciences Inc | DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS |
| CN113755421B (zh) * | 2021-09-28 | 2024-04-12 | 梦芊细胞因子有限公司 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
| JP2024536380A (ja) * | 2021-10-07 | 2024-10-04 | セキラス ピーティーワイ リミテッド | 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ |
| WO2025033553A1 (ja) * | 2023-08-10 | 2025-02-13 | 国立大学法人 東京大学 | 新規なｈｖｅｍ結合タンパク質およびそれを含む医薬組成物 |
| CN117153245B (zh) * | 2023-10-18 | 2024-03-19 | 无锡市疾病预防控制中心 | 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060240515A1 (en) * | 2003-07-21 | 2006-10-26 | Dimitrov Dimiter S | Soluble fragments of the SARS-CoV spike glycoprotein |
| CA2595780A1 (en) * | 2005-02-08 | 2006-08-17 | Shibo Jiang | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus |
| CN101522208A (zh) * | 2005-02-08 | 2009-09-02 | 纽约血库公司 | 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体 |
| LT2285408T (lt) * | 2008-06-05 | 2019-01-25 | Ablynx N.V. | Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui |
| WO2017196847A1 (en) * | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
-
2021
- 2021-02-05 EP EP21712040.1A patent/EP4100055A2/en active Pending
- 2021-02-05 KR KR1020227030791A patent/KR20220166787A/ko not_active Abandoned
- 2021-02-05 CN CN202180027079.5A patent/CN116234569A/zh active Pending
- 2021-02-05 AU AU2021217563A patent/AU2021217563A1/en active Pending
- 2021-02-05 US US17/760,300 patent/US20230227537A1/en not_active Abandoned
- 2021-02-05 JP JP2022548140A patent/JP2023516280A/ja active Pending
- 2021-02-05 CA CA3166967A patent/CA3166967A1/en active Pending
- 2021-02-05 IL IL295389A patent/IL295389A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516280A5 (https=) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP6850255B2 (ja) | 抗−ｃｄ４７抗体及びその使用 | |
| JP7195142B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| US20050288491A1 (en) | Super-humanized antibodies against respiratory syncytial virus | |
| JP7663977B2 (ja) | 抗ｐｄ―ｌ１抗体およびその用途 | |
| JP2024150445A5 (https=) | ||
| US10654943B2 (en) | Tri-specific antibodies for HIV therapy | |
| JP2018537966A (ja) | Ｈｉｖ感染症の予防または処置のための三重特異性および／または三価結合タンパク質 | |
| JP2018512138A5 (https=) | ||
| JP2016529882A5 (https=) | ||
| JP2010513539A5 (https=) | ||
| CN114736291B (zh) | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 | |
| JP2018509889A5 (https=) | ||
| KR101682040B1 (ko) | Ｍｓｒｖ 관련 질환에서 특이적 리간드의 치료적 용도 | |
| JP2023536654A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| JP2022531556A5 (https=) | ||
| JP2024506020A5 (https=) | ||
| WO2021148884A1 (en) | Anti-wuhan coronavirus antibodies | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2023537958A5 (https=) | ||
| JP2022502024A5 (https=) | ||
| JP2022529340A (ja) | ヒトｃｄ４７を標的とする抗体 | |
| JP2023538518A5 (https=) |